Loading…
Employees: 1,242
Size Guangdong Biolight Meditech (300246.SZ) is a China Health Care company (Medical Specialties) with a market value of $519M, the 3782nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥13.06 on 6 Nov 2026.
Performance Over six months the shares fell 22.8%, against -12.4% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 4.2% over the last twelve months (peer median +1.7%); the operating margin is -8.7% (peer median 0.1%).
Valuation It trades at 3.4× enterprise value to sales against a peer median of 5.0× (9th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 11.3 points below its cost of capital (6.1% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.09B | CN¥1.09B | CN¥1.06B | CN¥1.19B | CN¥1.18B |
| Revenue growth | — | +3% | -11% | +1% | — |
| Gross profit | CN¥239M | CN¥251M | CN¥249M | CN¥353M | CN¥327M |
| EBITDA | -CN¥5.30M | CN¥38.2M | CN¥5.71M | CN¥93.1M | CN¥48.2M |
| Net income | -CN¥105M | -CN¥69.4M | -CN¥71.4M | -CN¥65.2M | CN¥22.1M |
| Free cash flow | CN¥89.4M | -CN¥50.7M | -CN¥104M | -CN¥90.2M | -CN¥70.8M |
| Capital expenditure | CN¥93.7M | CN¥167M | CN¥104M | CN¥220M | CN¥212M |
| Total debt | CN¥753M | CN¥805M | CN¥712M | CN¥686M | CN¥475M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300246.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.5% | -2.3% | 2nd lowest of 21 |
| 6-month return | -22.8% | -12.4% | 4th lowest of 21 |
| Distance from 52-week high | -40.6% | -37.2% | 9th lowest of 21 |
| Revenue growth (TTM) | +4.2% | +1.7% | 10th highest of 21 |
| Operating margin | -8.7% | 0.1% | 7th lowest of 21 |
| EV / Sales | 3.4× | 5.0× | 9th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 14.8% | 7.4% | 4th most demanding of 12 |
| Growth delivered (Del g) | -4.7% | +7.7% | 3rd lowest of 12 |
| Hurdle (Req g minus delivered) | +19.5 pp | +0.5 pp | 2nd most demanding of 12 |
| ROIC minus cost of capital | -11.3 pp | -6.5 pp | 7th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | 3.4× | 14.8% | -4.7% |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | -2% | 4.5× | 10.1% | +120.2% |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 13% | 1.6× | -3.9% | -4.3% |
| AVITA Medical RCEL | United States | $513M | +304% | +1% | -47% | 7.3× | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 2% | 26.5× | n/a | n/a |
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 6% | 1.5× | 5.0% | +5.0% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $537M | -32% | +9% | 3% | 2.3× | n/a | n/a |
| Assure Tech (Hangzhou) 688075.SS | China | $538M | -25% | -21% | -7% | n/a | n/a | n/a |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -51% | n/a | n/a | n/a |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $542M | -3% | +23% | 31% | 8.0× | 6.3% | +24.4% |
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 14% | 5.5× | 19.3% | +12.4% |
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -6% | 1.4× | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 6.0× | 22.3% | +4.2% |
| WELL LEAD MEDICAL 603309.SS | China | $486M | -19% | +1% | 15% | 2.0× | -5.6% | +7.7% |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | 134.2× | n/a | n/a |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 6.0× | 6.5% | +10.0% |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | 6.2× | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | 1.7× | 7.4% | -7.8% |
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 1.2× | 11.5% | +11.0% |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -12% | 7.5× | 35.5% | -6.9% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | 2.0× | n/a | n/a |